share_log

Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Gibson Christopher

Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Gibson Christopher

Recursion Pharmaceuticals | 4:持股變動聲明-高管 Gibson Christopher
美股sec公告 ·  06/07 16:09
Moomoo AI 已提取核心訊息
Recursion Pharmaceuticals CEO Christopher Gibson completed a series of transactions involving the company's Class A Common Stock on June 5th and 6th, 2024. On June 5th, Gibson acquired 25,000 shares at no cost and disposed of the same number as a bona fide gift. Additionally, he sold 50,000 shares at $8.42 each. The following day, Gibson sold another 50,000 shares, this time at $9.00 per share. After these transactions, Gibson's direct holdings in Recursion Pharmaceuticals totaled 708,738 shares. The total market value of the disposed shares amounted to $871,000.
Recursion Pharmaceuticals CEO Christopher Gibson completed a series of transactions involving the company's Class A Common Stock on June 5th and 6th, 2024. On June 5th, Gibson acquired 25,000 shares at no cost and disposed of the same number as a bona fide gift. Additionally, he sold 50,000 shares at $8.42 each. The following day, Gibson sold another 50,000 shares, this time at $9.00 per share. After these transactions, Gibson's direct holdings in Recursion Pharmaceuticals totaled 708,738 shares. The total market value of the disposed shares amounted to $871,000.
Recursion Pharmaceuticals的CEO Christopher Gibson在2024年6月5日和6日完成了一系列與該公司的A類普通股有關的交易。6月5日,Gibson免費取得了25000股,並以真實禮物的名義出售了同樣數量的股份。此外,他以每股8.42美元的價格出售了50,000股。次日,Gibson以每股9.00美元的價格再次出售了50,000股。這些交易之後,Gibson在Recursion Pharmaceuticals持有的直接股份總計爲708,738股。已處理股份的總市場價值爲871,000美元。
Recursion Pharmaceuticals的CEO Christopher Gibson在2024年6月5日和6日完成了一系列與該公司的A類普通股有關的交易。6月5日,Gibson免費取得了25000股,並以真實禮物的名義出售了同樣數量的股份。此外,他以每股8.42美元的價格出售了50,000股。次日,Gibson以每股9.00美元的價格再次出售了50,000股。這些交易之後,Gibson在Recursion Pharmaceuticals持有的直接股份總計爲708,738股。已處理股份的總市場價值爲871,000美元。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息